Wissenschaftliche Arbeiten

Prof. Dr. Cafer Adıgüzel

142 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.

Zurück zum Profil

  1. A1. Kantarcioglu B, Iqbal O, Lewis J, Carter CA, Singh M, Lievano F, Ligocki M, Jeske W, Adiguzel C, Gerotziafas GT, Fareed J.An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations. Clin Appl Thromb Hemost. 2022 Jan-Dec;28

    Quelle: Profilseite auf medicana.com.tr

  2. A2. Umit EG, Kara O, Adiguzel C. (Re: Schelfhout J, Bonafede M, Cappell K, et al. Impact of cytomegalovirus complications on resource utilization and costs following hematopoietic stem cell transplant. Curr Med Res Opin. 2020; 36(1):33-41. Schelfhout J, Brown H, House JA, Raval AD. Cytomegalovirus infection and associated hospitalization and costs among individuals undergoing allogeneic hematopoietic stem cell transplant. Curr Med Res Opin. 2020;36(1):43-50.) Curr Med Res Opin. 2020 Apr;36(4):607.

    Quelle: Profilseite auf medicana.com.tr

  3. A3. Yabas Kiziloglu O, Mestanoglu M, Totuk Gedar OM, Adiguzel C, Toygar O. Recurrence of acute lymphoblastic leukemia manifesting as serous retinal detachments and optic disc swelling.Int Ophthalmol. 2018 Aug;38(4):1791-1795.

    Quelle: Profilseite auf medicana.com.tr

  4. A4. Kantarcıoğlu B, Türköz HK, Yılmaz G, Pepedil Tanrıkulu F, Kaygusuz Atagündüz I, Adıgüzel C, Fıratlı Tuğlular T. Aplastic anemia associated with oral terbinafine: a case report and review of the literature. Turk J Haematol. 2014 Dec 5;31(4):411-6.

    Quelle: Profilseite auf medicana.com.tr

  5. A5. Toptas T, Kaygusuz-Atagunduz I, Kani HT, Adiguzel C, Firatli-Tuglular T. Levofloxacin for the treatment of severe refractory BK virus-associated hemorrhagic cystitis in hematopoietic stem cell transplantation recipients: A report of three cases. Oncol Lett. 2014 Oct;8(4):1775-1777.

    Quelle: Profilseite auf medicana.com.tr

  6. A6. Fareed J, Adiguzel C, Thethi I.Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism. Thromb J. 2011 Mar 28;9(1):5.

    Quelle: Profilseite auf medicana.com.tr

  7. A7. Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract . 64(7):956-67 (2010).

    Quelle: Profilseite auf medicana.com.tr

  8. A8. Kaygusuz I, Koc M, Arikan H, Adiguzel C, Cakalagaoglu F, Tuglular TF, Akoglu E. Focal segmental glomerulosclerosis associated with idiopathic myelofibrosis. Ren Fail. 32(2):273-6 (2010).

    Quelle: Profilseite auf medicana.com.tr

  9. A9. Knesek MJ, Litinas E, Adiguzel C, Hopkinson W, Hoppensteadt D, Lassen M, Fareed J. Inflammatory biomarker profiling in elderly patients with acute hip fracture treated with heparins. Clin Appl Thromb Hemost. 16(1):42-50 (2010).

    Quelle: Profilseite auf medicana.com.tr

  10. A10. Zhu H, Hoppensteadt D, Iqbal O, Litinas E, Adiguzel C, Fareed J. Relative purity of different bovine thrombin preparations. Clin Appl Thromb Hemost. 15(6):681-8 (2009).

    Quelle: Profilseite auf medicana.com.tr

  11. A11. Adiguzel C, Iqbal O, Demir M, Fareed J. European community and US-FDA approval of recombinant human antithrombin produced in genetically altered goats. Clin Appl Thromb Hemost. 15(6):645-51 (2009).

    Quelle: Profilseite auf medicana.com.tr

  12. A12. Sayitoglu, M., I.C. Haznedaroğlu, O. Hatirnaz, Y. Erbilgin, S. Aksu, E. Koca, C. Adiguzel, M. Bayik, I. Akalin, Z. Gülbas, M. Akay, A. Unal, L. Kaynar, E. Ovali, M. Yilmaz, M. Yenerel, S. Dagdas, G. Ozet, C. Ar, Y. Aydin, T. Soysal, B. Durgun, O. Ozcebe, A. Tukun, O. Ilhan ve U.Ozbek. “Effects of Imatinib Mesylate on Renin-Angiotensin System (RAS) Activity During the Clinical Course of Chronic Myeloid Leukaemia” J Int Med Res, 37, 1018-1028 (2009).

    Quelle: Profilseite auf medicana.com.tr

  13. A13. Adiguzel, C., O. Iqbal, D. Hoppensteadt, W. Jeske, J. Cunanan, E. Litinas, H. Zhu, J.M. Walenga ve J. Fareed. “Comparative Anticoagulant and Platelet Modulatory Effects of Enoxaparin and Sulodexide”. Clin Appl Thromb Hemost, 15(5):501-11. (2009).

    Quelle: Profilseite auf medicana.com.tr

  14. A14. Kannan, M., R. Saxena, C. Adiguzel ve J. Fareed. An update on the prevalence and characterization of H-PF4 antibodies in Asian-Indian patients. Semin Thromb Hemost , 35, 337-343 (2009).

    Quelle: Profilseite auf medicana.com.tr

  15. A15. Adiguzel, C., V. Bansal, E. Litinas, J. Cunanan, O. Iqbal, K. Nelson, M. Kannan, D. Hoppensteadt ve J. Fareed. “Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin”. Clin Appl Thromb Hemost, 15, 145-151 (2009).

    Quelle: Profilseite auf medicana.com.tr

  16. A16. Adiguzel, C., W.P. Jeske, D. Hoppensteadt, J.M. Walenga, V. Bansal ve Fareed J. “Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products”. Clin Appl Thromb Hemost, 15, 137-144 (2009).

    Quelle: Profilseite auf medicana.com.tr

  17. A17. Adiguzel, C., S.U. Bozkurt, I. Kaygusuz, A. Uzay, Tecimer T, ve M. Bayik. “Human herpes virus 8-unrelated primary effusion lymphoma-like lymphoma: report of a rare case and review of the literature”. APMIS, 117, 222-229 (2009).

    Quelle: Profilseite auf medicana.com.tr

  18. A18. Heilmann, L., M. Schorch, T. Hahn, G. Adasz, K. Schilberz, C. Adiguzel ve J. Fareed. “Pregnancy outcome in women with antiphospholipid antibodies: report on a retrospective study”. Semin Thromb Hemos. 34, 794-802 (2008).

    Quelle: Profilseite auf medicana.com.tr

  19. A19. Zhu, H., D. Hoppensteadt, C. Adiguzel, R.L. Bick ve J. Fareed. “Comparison of immunogenic potentials of bovine thrombin preparations”. Clin Appl Thromb Hemost, 15, 41-49 (2009).

    Quelle: Profilseite auf medicana.com.tr

  20. A20. Zhu, H., D. Hoppensteadt, R. Wahi, J. Cunanan, C. Adiguzel, R. Bick ve J. Fareed. “Reduced Immunogenic Potential of Membrane Filtered Bovine Thrombin Preparations for Hemostatic Application”. Clin Appl Thromb Hemost, 15, 32-40 (2009).

    Quelle: Profilseite auf medicana.com.tr

  21. A21. Clark, M., D. Hoppensteadt, J. Walenga, L. Myers, J. Cunanan, W. Jeske, C. Adiguzel, O. Iqbal ve J. Fareed. “Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate”. Int Angiol, 27, 370-376 (2008).

    Quelle: Profilseite auf medicana.com.tr

  22. A22. Iqbal, O., C. Adiguzel, B.E. Lewis, J. Cunanan ve J. Fareed. “Argatroban in percutaneous Coronary interventions”. Semin Thromb Hemost, 34(Suppl 1), 62-74 (2008).

    Quelle: Profilseite auf medicana.com.tr

  23. A23. Adiguzel, C., O. Iqbal, J. Cunanan, W. Jeske, D. Hoppensteadt, J.M. Walenga ve J. Fareed. “Potency adjusted generic versions of argatroban can be differentiated from branded argatroban in thrombin generation and platelet activation assays”. Semin Thromb Hemost, 34(Suppl 1), 108-117 (2008).

    Quelle: Profilseite auf medicana.com.tr

  24. A24. Fareed, J., J.M. Walenga, W. Jeske, D. Hoppensteadt, M. Prechel, O. Iqbal, C. Adiguzel, M. Clark, E. Litinas, J. Cunanan, R. Linhardt ve J. Harenberg. “Biological profile of the hyper/oversulfated chondroitin sulfate contaminant isolated from recall heparin”. Semin Thromb Hemost, 34(Suppl 1), 119-127 (2008).

    Quelle: Profilseite auf medicana.com.tr

  25. A25. Fareed, J., W. Jeske, D. Fareed, M. Clark, R. Wahi, C. Adiguzel ve D. Hoppensteadt. “Are all low molecular weight heparins equivalent in the management of venous thromboembolism?” Clin Appl Thromb Hemost, 14, 385-392 (2008).

    Quelle: Profilseite auf medicana.com.tr

  26. A26. Hoppensteadt, D.A., R. Wahi, C. Adiguzel, O. Iqbal, E. Ramacciotti, R.L. Bick, H.L. Messmore, V. Bansal ve Fareed J. “Contaminant in the recalled unfractionated heparin preparations: where is the problem?” Clin Appl Thromb Hemost, 14, 261-266 (2008).

    Quelle: Profilseite auf medicana.com.tr

  27. A27. Fareed, J., O. Iqbal, J. Cunanan, M. Demir, R. Wahi, M. Clarke, C. Adiguzel ve R. Bick. “Chaining trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?” Int Angiol, 27, 176-192 (2008).

    Quelle: Profilseite auf medicana.com.tr

  28. A28. Fareed, J., D.A. Hoppensteadt, D. Fareed, M. Demir, R. Wahi, M. Clarke, C. Adiguzel ve R. Bick. “Survival of heparins, oral anticoagulants, and aspirin after the year 2010”. Semin Thromb Hemost, 34, 58-73 (2008).

    Quelle: Profilseite auf medicana.com.tr

  29. A29. Jeske, W.P., J.M. Walenga, D.A. Hoppensteadt, C. Vandenberg, A. Brubaker, C. Adiguzel, M. Bakhos ve J. Fareed. “Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic”. Semin Thromb Hemost, 34, 74-85 (2008).

    Quelle: Profilseite auf medicana.com.tr

  30. A30. Hoppensteadt, D.A., N. Fabbrini, R.L. Bick, H.L. Messmore, C. Adiguzel, J. Fareed. “Laboratory evaluation of the antiphospholipid syndrome”. Hematol Oncol Clin North Am, 22, 19-32 (2008).

    Quelle: Profilseite auf medicana.com.tr

  31. A31. Bizargity, P., C. Adıguzel, G. Ozilhan, M. Bayık ve E. Eksioglu-Demiralp. “İmatinib does not inhibit neutrophil oxidative burst function in patients with chronic myelogenous leukemia”. Clin Lab Haem: 27:1-2 (2005).

    Quelle: Profilseite auf medicana.com.tr

  32. A32. Cetiner, M., C. Adıgüzel, D. Argon, S. Ratip, E. Ekşioğlu-Demiralp, T. Tecimer ve M. Bayık. “Hairy Cell Leukemia in Father and Son”. Med Oncol, 20, 375-378 (2003).

    Quelle: Profilseite auf medicana.com.tr

  33. A33. Demirçay, Z., A. Cömert ve C. Adıgüzel. “Leg Ulsers and Hydroxyurea: Report of Three Cases with Essential Thrombocythemia”. İnternational Journal of Dermatology, 41, 872-874 (2002).

    Quelle: Profilseite auf medicana.com.tr

  34. B1. Dilvin Guney, Aysin Tulunay, Funda Pepedil, Isik Kaygusuz, Cafer Adiguzel, Tülin Tuglular, Muzaffer Demir, Emel Eksioglu-Demiralp, and Fikriye Uras. Tyro3, Axl Ve Mer (TAM) Receptors On Surfaces of Mononuclear Cells in Patients with B-Cell Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: 4588.

    Quelle: Profilseite auf medicana.com.tr

  35. B2. Debra Hoppensteadt, Hussein Khan, Indermohan Thethi, Muzaffer Demir, Cafer Adiguzel, Saud Rahman, and Jawed Fareed. Inflammatory and Thrombotic Mediators in Small Cell Lung Carcinoma: Potential Role in Thromboembolic Complications. Blood (ASH Annual Meeting Abstracts), Nov 2011; 118: 2294.

    Quelle: Profilseite auf medicana.com.tr

  36. B3. Jawed Fareed, Cafer Adiguzel, Debra Hoppensteadt, Walter Jeske, Jeanine M. Walenga, Bruce E Lewis, Harry L. Messmore, Jr., and Vinod Bansal. Prevalence of Heparin Induced Thrombocytopenia Antibodies During the Period 2004–2011. Relevance to Heparin Contaminants. Blood (ASH Annual Meeting Abstracts), Nov 2011; 118: 4326.

    Quelle: Profilseite auf medicana.com.tr

  37. B4. Microscopic Examination Of Bone Marrow Aspiration Smears: Diagnostic Agreement Of Hematologists And Hematopathologists On Common Hematological Diagnoses T Toptas, M Sungurtekin, G Gokoglu, M Gun, T Kasikci, G Yilmaz, B Kantarcioglu, I Kaygusuz, C Adiguzel, S Bozkurt, T Firatli-Tuglular, M Bayik. 16th Congress of the European Hematology Association London, 2011 (1755).

    Quelle: Profilseite auf medicana.com.tr

  38. B5. Levofloxacin For Bk Virus-Associated Hemorrhagic Cystitis In The Post-Hematopoietic Stem Cell Transplantation Period T Toptas, I Kaygusuz, T Kani, B Kantarcioglu, G Yilmaz, C Adiguzel, T Firatli-Tuglular, M Bayik. 16th Congress of the European Hematology Association London, 2011 (1495).

    Quelle: Profilseite auf medicana.com.tr

  39. B6. The Effect Of Complete Molecular Response On Progression-Free Survival In Patients With Chronic Myeloid Leukemia Receiving Imatinib Mesylate I Kaygusuz, T Toptas, B Kantarcioglu, G Yilmaz, C Adiguzel, E Eksioglu-Demiralp, T Firatli-Tuglular, M Bayik 16th Congress of the European Hematology Association London, 2011 (0154).

    Quelle: Profilseite auf medicana.com.tr

  40. B7. Jawed Fareed, Debra Hoppensteadt, Josephine Cunanan, Walter Jeske, Cafer Adiguzel, He Zhu, Cinara Echart, and Massimo Iacobelli. Prolonged Administration of Defibrotide Is Non-Immunogenic in Rats and Dogs. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 4180.

    Quelle: Profilseite auf medicana.com.tr

  41. B8. Walenga, J., M. Bakhos, D. Hoppensteadt, C. Adiguzel, J. Cunanan ve W. Jeske. “Immunogenicity Of Low Molecular Weight Heparins And Biosimilars”. Journal of Thrombosis and Haemostasis, 7 (Suppl 2), PP-MO-399, 2009, (XXII Congress of the International Society of Thrombosis and Haemostasis, Boston, MA, USA, 11-16 July 2009).

    Quelle: Profilseite auf medicana.com.tr

  42. B9. Gray, A., D. Hoppensteadt, L. Myers, O. Iqbal, C. Adiguzel, ve J. Fareed. “Assay Dependent Variations In The USP Potency Standardized Unfractionated Heparins”. Journal of Thrombosis and Haemostasis, 7 (Suppl 2), PP-MO-136, 2009, (XXII Congress of the International Society of Thrombosis and Haemostasis, Boston, MA, USA, 11-16 July 2009).

    Quelle: Profilseite auf medicana.com.tr

  43. B10. Adiguzel, C., E. Litinas, J. Cunanan, D. Hoppensteadt, J. Walenga ve J. Fareed. “Differential Thrombin Generation Inhibition By Branded And Generic Low Molecular Weight Heparins (LMWHs) As Studied By Using Fluorescence Substrate Based Kinetic Method”. Journal of Thrombosis and Haemostasis, 7 (Suppl 2), PP-MO-139, 2009, (XXII Congress of the International Society of Thrombosis and Haemostasis, Boston, MA, USA, 11-16 July 2009).

    Quelle: Profilseite auf medicana.com.tr

  44. B11. Adiguzel, C., J. Fareed, J. Walenga, D. Hoppensteadt, W. Jeske, O. Iqbal, J. Cunanan ve E. Litinas. “Generic Versions Of Argatroban Can Be Differentiated From Branded Argatroban In The Thrombin Generation Assays (Tga)”. Journal of Thrombosis and Haemostasis. 7 (Suppl 2), PP-MO-140, 2009, (XXII Congress of the International Society of Thrombosis and Haemostasis, Boston, MA, USA, 11-16 July 2009).

    Quelle: Profilseite auf medicana.com.tr

  45. B12. Hoppensteadt, D., J. Fareed, V. Bansal, O. Iqbal, C. Adiguzel ve H. Messmore. “Activation Of Prekallikrein By Contaminated Heparins, Isolated Contaminant And Related Hypersulfated Chondroitin Sulfate Preparations: Pharmacologic Implications”. Journal of Thrombosis and Haemostasis, 7 (Suppl 2), PP-MO-143, 2009, (XXII Congress of the International Society of Thrombosis and Haemostasis, Boston, MA, USA, 11-16 July 2009).

    Quelle: Profilseite auf medicana.com.tr

  46. B13. Bansal, V., E. Litinas, D. Hoppensteadt, C. Adiguzel ve Jawed Fareed. “Contaminants In Heparin! A Call For Substitute Anticoagulants”. Journal of Thrombosis and Haemostasis, 7 (Suppl 2), PP-TH-145, 2009, (XXII Congress of the International Society of Thrombosis and Haemostasis, Boston, MA, USA, 11-16 July 2009).

    Quelle: Profilseite auf medicana.com.tr

  47. B14. Bansal, V., J. Cunanan, D. Hoppensteadt, C. Adiguzel, O. Iqbal ve J. Fareed. “Fibrinokinetic Deficit In Chronic Kidney Disease And End Stage Renal Disease Patients Contributes To The Hemostatic Abnormalities”. Journal of Thrombosis and Haemostasis, 7 (Suppl 2), PP-WE-261, 2009, (XXII Congress of the International Society of Thrombosis and Haemostasis, Boston, MA, USA, 11-16 July 2009).

    Quelle: Profilseite auf medicana.com.tr

  48. B15. Adiguzel, C., J. Walenga, H. Messmore, , D. Hoppensteadt, R. Wahi, ve J. Fareed, “

    Quelle: Profilseite auf medicana.com.tr

  49. Bioavailability Of Over Sulfated Chondroitin Sulfate. Immunologic Implications”. Journal of Thrombosis and Haemostasis, 7 (Suppl 2), PP-TH-390, 2009, (XXII Congress of the International Society of Thrombosis and Haemostasis, Boston, MA, USA, 11-16 July 2009)

    Quelle: Profilseite auf medicana.com.tr

  50. B16. Litinas, E., C. Adiguzel, W. Jeske, D. Hoppensteadt, H. Messmore, J. Walenga ve J. Fareed. “

    Quelle: Profilseite auf medicana.com.tr